Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.73 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | MITF | O75030 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.63 |
| ▸ | XBP1 | P17861 | 1/20 | 0.63 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | HTT | P42858 | 4/20 | 0.61 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9081388 | 0.89 | NPC1 (0.76) | POLBNPC1MITFRAB9ANPSR1 | |
| SCHEMBL6408760 | 0.86 | POLB (0.71) | POLBNPC1MITFRAB9ANPSR1 | |
| Toluene SCHEMBL27921176 | 0.86 | ALDH1A1 (0.66) | POLBNPC1MITFRAB9ANPSR1 | |
| SCHEMBL8141144 | 0.85 | POLB (1.00) | POLBNPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL28778390 | 0.84 | POLB (0.68) | POLBNPC1RAB9AALDH1A1MAPT | |
| SCHEMBL5903996 | 0.83 | ALDH1A1 (0.67) | POLBNPC1MITFRAB9ANPSR1 | |
| SCHEMBL14578751 | 0.83 | POLB (0.85) | POLBNPC1RAB9AALDH1A1MAPT | |
| SCHEMBL16922181 | 0.81 | NPC1 (0.66) | POLBNPC1MITFRAB9ANPSR1 | |
| SCHEMBL2093671 | 0.81 | POLB (0.76) | POLBNPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL2635734 | 0.81 | NPC1 (0.66) | NPC1MITFRAB9ANPSR1XBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109232544-A | A kind of preparation method of prucalopride | 江苏工程职业技术学院 | 2019-01-18 | — | — | CN | claimed |
| US-7906677-B2 | Process for phenylacetic acid derivatives | NOVARTIS AG (CH) | 2011-03-15 | — | — | US | claimed |
| EP-2275403-A1 | Process for phenylacetic acid derivatives | Novartis AG (CH) | 2011-01-19 | — | — | EP | claimed |
| US-20090275758-A1 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2009-11-05 | — | — | US | claimed |
| EP-1216226-B1 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2009-11-04 | — | — | EP | claimed |
| US-20080249318-A1 | Process for phenylacetic acid derivatives | ACEMOGLU MURAT | 2008-10-09 | — | — | US | claimed |
| JP-2003510303-A | — | — | 2003-03-18 | — | — | JP | claimed |
| EP-1216226-A2 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | Novartis AG (CH) | 2002-06-26 | — | — | EP | claimed |
| WO-2001023346-A2 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2001-04-05 | — | — | WO | claimed |
| CN-117658932-A | Amino dithioester derivative containing amide structural unit, and preparation method and application thereof | 郑州大学 | 2024-03-08 | — | — | CN | disclosed |
| US-20240018135-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF | MEDIFRON DBT INC. (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20240018135-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF | MEDIFRON DBT INC. (KR) | 2024-01-18 | — | — | US | disclosed |
| CN-116947772-A | 1,2, 4-triazole-phenylacetamide alpha-glucosidase inhibitor and preparation method and application thereof | 贵州医科大学 | 2023-10-27 | — | — | CN | disclosed |
| CN-116438167-A | Compounds having O-GlcNAc enzyme inhibitory activity and uses thereof | 美迪福伦DBT有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-4567264-A | ADRENERGIC BLOCKING AGENTS | SYNTEX (U.S.A.) INC. (US) | 1986-01-28 | — | — | US | disclosed |
| US-4558129-A | Benzodioxanyl-hydroxyethylene-piperazinyl acetanilides which effect calcium entry and β-blockade | SYNTEX (U.S.A.) INC. (US) | 1985-12-10 | — | — | US | disclosed |
| US-4499100-A | CARDIOUVASCULAR DISORDERS | SYNTEX (U.S.A.) INC. (US) | 1985-02-12 | — | — | US | disclosed |
| EP-0126449-A1 | Cardioselective aryloxy- and arylthio-hydroxypropyl piperazinyl acetanilides wich affect calcium entry | SYNTEX (U.S.A.) INC. (US) | 1984-11-28 | — | — | EP | disclosed |
| US-3991202-A | ANTIMICROBIALS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-11-09 | — | — | US | disclosed |
| US-3972928-A | Regulating plant growth with quaternary phosphonium aliphatic carboxamide salts | BAYCHEM CORPORATION (US) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249318-A1 | Process for phenylacetic acid derivatives | ALDH7A1, CYP4F11, CYP2A6 | POLB 2347/4885NPC1 3422/4885MITF 2187/4885 |
| US-20240018135-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF | OGA, OGT, ENGASE | POLB 3871/4885NPC1 3307/4885MITF 2149/4885 |
| US-20090275758-A1 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | ALDH7A1, CYP4F11, CYP2A6 | POLB 2347/4885NPC1 3422/4885MITF 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.